TriangleFOR PATIENTS · SOURCE READING
Treatment of Childhood Chronic Myelogenous Leukemia
Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 5, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Childhood CML source section; source uses myelogenous wording Only the named source sections and descendants are joined. Parent source is broader; original patient terminology and grade/setting constraints must remain visible.
For information about the treatments listed below, see the Treatment Option Overview section.
Source links and citations
Treatment of newly diagnosed chronic myelogenous leukemia (CML) may include the following:
Source links and citations
Targeted therapy with a tyrosine kinase inhibitor (imatinib, dasatinib, or nilotinib).
Source links and citations
A clinical trial to study the rate of CML recurrence after stopping tyrosine kinase inhibitor therapy, and the ability to achieve remission again if CML recurs in children with CML who are in remission for at least 2 years after receiving treatment with the same tyrosine kinase inhibitor for at least 3 years.
Source links and citations
Treatment of refractory or recurrent childhood CML may include the following:
Source links and citations
Targeted therapy with a tyrosine kinase inhibitor (dasatinib or nilotinib).
Stem cell transplant using blood stem cells from a donor.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice